What preventive measures and acute management should a young adult follow for respiratory infections such as influenza and COVID‑19?

Respiratory Infection Prevention and Management in Young Adults

For young adults, prioritize annual influenza and COVID-19 vaccination as the single most effective preventive measure, and if symptomatic with confirmed COVID-19 within 5 days of onset and at high risk, use nirmatrelvir-ritonavir as first-line antiviral therapy 1, 2.

Prevention Strategy

Vaccination (Primary Prevention)

• Get annual influenza vaccination - this remains the most effective preventive measure against influenza 3, 4
• Maintain up-to-date COVID-19 vaccination - vaccination is the single most effective intervention for reducing severe disease risk 1
• Vaccination should be actively pursued even in vaccine-hesitant individuals 1, 2

Non-Pharmaceutical Measures

• Masking during high community transmission periods - both source control and exposure control decrease transmission risk, with respirators providing greater protection than surgical masks 5
• Practice infection control measures including case isolation when symptomatic 1
• These measures are particularly important during peak viral activity seasons 5

Acute Management of COVID-19

Initial Assessment

Assess for:

• Disease severity (mild, moderate, severe)
• Risk factors for progression: older age, severe immunocompromise, significant comorbidities 1
• Timing of symptom onset (critical for antiviral eligibility)

Antiviral Therapy Decision Algorithm

For patients at high risk of progression:

• Start within 5 days of symptom onset for maximum effectiveness 1
• First-line: Nirmatrelvir-ritonavir (if no contraindications) 1
  • Major caveat: extensive drug interactions require careful medication review
• Second-line: Molnupiravir (when nirmatrelvir-ritonavir unsuitable) 1

For otherwise healthy young adults with mild disease:

• Antiviral therapy is NOT routinely indicated given high cost, potential adverse effects, and uncertain clinical benefit in low-risk populations 1

Symptom Management in Community Setting

For fever:

• Advise regular fluid intake (maximum 2 liters daily) 6
• Use paracetamol (acetaminophen) for symptomatic relief - preferred over NSAIDs until more evidence available 6
• Do NOT use antipyretics solely to reduce temperature 6
• Continue only while fever and associated symptoms persist 6

For cough:

• Avoid lying flat (makes coughing ineffective) 6
• Try honey first (age >1 year) 6
• For distressing cough: consider short-term codeine linctus, codeine phosphate, or morphine sulfate oral solution 6

For breathlessness:

• Non-pharmacological techniques first:
  • Sit upright to increase peak ventilation 6
  • Lean forward with arms bracing (improves ventilatory capacity) 6
  • Pursed-lip breathing: inhale through nose, exhale slowly through pursed lips for 4-6 seconds 6
  • Drop and relax shoulders to reduce anxiety-driven hunched posture 6

What NOT to use in mild-moderate community COVID-19:

• No inhaled or oral glucocorticoids 1
• No immune therapies 1
• These have no role in routine community treatment

Hospitalization Criteria

Refer to hospital if signs of severe or critical disease develop 1:

• Significant respiratory distress
• Hypoxemia requiring supplemental oxygen
• Rapid clinical deterioration

Acute Management of Influenza

Antiviral Treatment (Based on WHO 2024 Guidelines)

For severe influenza:

• Oseltamivir within 48 hours of symptom onset (conditional recommendation) 7

For non-severe influenza in high-risk patients:

• Baloxavir to prevent progression to severe illness (conditional recommendation) 7

Post-exposure prophylaxis indications:

• Exposure to zoonotic influenza (any person) 7
• Exposure to seasonal influenza in extremely high-risk individuals 7
• Options: baloxavir, laninimavir, oseltamivir, or zanamivir 7

What NOT to Use for Influenza

Strong recommendation AGAINST:

• Antibiotics in non-severe influenza 7

Conditional recommendations AGAINST in severe influenza:

• Corticosteroids 7
• Macrolides 7
• mTOR inhibitors 7
• NSAIDs 7
• Passive immune therapy 7

Critical Pitfalls to Avoid

1. Timing matters: Antivirals for both COVID-19 and influenza are most effective within 5 days (COVID) or 48 hours (influenza) of symptom onset 1, 7

2. Drug interactions with nirmatrelvir-ritonavir: Extensive interactions require thorough medication review before prescribing 1

3. Avoid unnecessary antibiotics: Strong evidence against routine antibiotic use in non-severe influenza 7

4. Don't use corticosteroids for mild-moderate COVID-19 in community: Reserved for hospitalized patients requiring oxygen 8, 1

5. Early testing is essential: Prompt recognition of symptoms and testing enables timely antiviral initiation 2